Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/22/2005US20050282854 Amide substituted imidazopyridines
12/22/2005US20050282853 microbial infections from a protozoan pathogen, such as Trypanosoma brucei rhodesiense and Plasmodium falciparum; 2,6-Bis[4-(N-hydroxyamidino-phenyl)]-imidazo[1,2-a]pyridine; reacting an aryl-substituted alkylketone halide with an aminopyridine; adding a cyanophenyl-boronic acid
12/22/2005US20050282852 Preventive and therapeutic medicament for gastroesophageal reflux disease
12/22/2005US20050282851 antidiabetic agents such as 3-Cyclopentyl-2-(4-methanesulfonyl-phenyl)-N-(5-methoxy-thiazolo[5,4-b]pyridin-2-yl)-propionamide, used for prevention and treatment of impaired glucose tolerance, non-insulin dependent diabetes and obesity
12/22/2005US20050282850 Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid
12/22/2005US20050282849 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; can be coadministered with other anticarcinogenic agents; angiogenesis inhibitors;
12/22/2005US20050282847 Oxidizing a 4-substituted-2-thiopyrimidine and reacting the sulfone formed with an alkylcyanamide; both thio and sulfonyl intermediates of 4-substitutedaminopyridines are claimed, e.g., 4,6-dichloro-5-(2-chloro-6-fluorophenyl)-2-methylthiopyrimidine
12/22/2005US20050282846 Compounds capable of activating cholinergic receptors
12/22/2005US20050282845 Substituted pyrimidines as selective cyclooxygenase-2 inhibitors
12/22/2005US20050282843 Therapeutic applications of 2-substituted 4-heteroarylpyrimidines
12/22/2005US20050282842 Therapeutic compounds based on pyrazolopyridine derivatives
12/22/2005US20050282840 Methods of modulating neurotrophin-mediated activity
12/22/2005US20050282839 Pyrimidyl phosphonate antiviral compounds and methods of use
12/22/2005US20050282838 Compounds, compositions, and methods
12/22/2005US20050282837 for use as anticancer agents and in treatment of herpes virus; packs/kits for plaque reduction
12/22/2005US20050282836 Solid orally ingestible formulations of tetrodotoxin
12/22/2005US20050282835 Increasing growth of epithelial cells in the female reproductive tract by administering to the vaginal cavity a retinoid or a carotenoid; treating vaginal dryness for example; carrier, vitamin E, and jasmonic acid
12/22/2005US20050282834 Compositions, devices and methods for treating cardiovascular disease
12/22/2005US20050282833 Pharmacological treatment of psoriasis
12/22/2005US20050282832 composition for inhibition of opioid tolerance and opioid withdrawal-induced hyperalgesia comprising propentofylline, an opioid drug, and a pharmaceutically acceptable carrier, wherein said composition is administered intrathecally at a dose of propentofylline of 10 micrograms
12/22/2005US20050282831 Adenine derivatives, especially substituted with an alkynylene-, alkenylene-, alkadienylene- or alkynylenealkenylene- group; e.g., 2-{3-[1-(Methoxycarbanoyl)piperidin-4-yl]propyn-1-yl}-9-propargyladenine; stimulating motor activity without dyskinesia; treating Huntington's & Parkinson's diseases, etc.
12/22/2005US20050282830 Use of dipyridamole or mopidamole for treatment and prevention of MMP-9-dependent disorders
12/22/2005US20050282829 Furanopyrimidine compounds as potassium ion channel inhibitors
12/22/2005US20050282828 Fungicidal 5-phenyl substituted 2-(cyanoamino) pyrimidines
12/22/2005US20050282825 Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
12/22/2005US20050282824 Substituted pyrimidines as inhibitors of bacterial type III protein secretion systems
12/22/2005US20050282823 Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders
12/22/2005US20050282822 Therapeutic agents
12/22/2005US20050282821 Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
12/22/2005US20050282820 To a suspension of 2-(4-t-butylphenyl)-4-piperazin-1-yl-1H-benzimidazole and potassium carbonate in acetone was added 6-bromomethylquinoxaline to produce 2-(4-tert-butylphenyl)4-{[4-(6-quinoxalyl)methyl]piperazin-1-yl}benzimidazole Dihydrochloride Dihydrate
12/22/2005US20050282819 Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia
12/22/2005US20050282817 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; obesity
12/22/2005US20050282816 Pyrazinylmethyl lactam derivatives
12/22/2005US20050282815 Substituted N-(heteroar-beta-yl)aminopyridinecarboxamides or benzamides, e.g., 2-amino-4-fluoro-5-(1-methyl-1H-imidazol-2-ylsulfanyl)-N-(4-methylthiazol-2-yl)benzamide; glucokinase activators used to treat diabetes mellitus or obesity
12/22/2005US20050282814 Vasculostatic agents and methods of use thereof
12/22/2005US20050282813 imidazo(1,5-a)-pyrazine-1,3-dione derivatives; Anticancer agents; immune disorders; (5S,8S,8aR)-4-[Octahydro-7-[(1,1-dimethylethoxy)carbonyl]-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyrazin-2-yl]-2-(trifluoromethyl)benzonitrile
12/22/2005US20050282812 Inhibitors of cholesteryl ester transfer protein
12/22/2005US20050282811 Diazabicyclic histamine-3 receptor antagonists
12/22/2005US20050282810 Oxindole derivatives
12/22/2005US20050282809 Heteroaryl-hydrazone compounds
12/22/2005US20050282807 Such as (S)-(4-(ethylamino)-2-((4-methylpiperidin-1-yl)methyl)thiazol-5-yl)(2-(methoxymethyl)pyrrolidin-1-yl)methanone; for treatment of neurological and psychiatric disorders/diseases, cancer, and disorders mediated by protein kinase inhibition
12/22/2005US20050282806 2-(4-morpholinyl)ethyl (E)-6-(1,3-dihydro-4-[2-(4-morpholinyl)ethoxy]-6-methoxy-7-methyl-3-oxo-isobenzofuran-5-yl)-4-methyl-hex-4-enoate; use as reference marker in HPLC study of pharmacology and toxicology; combining mycophenolate mofetil with 4-(2-chloroethyl)-morpholine hydrochloride
12/22/2005US20050282805 Five-membered heterocycles useful as serine protease inhibitors
12/22/2005US20050282804 Process for preparing 10alpha-[4'-(S,S-dioxothiomorpholin-1'-yl)]-10-deoxo-10-dihydroartemisinin
12/22/2005US20050282803 CIS-imidazolines
12/22/2005US20050282802 double salts of N-(3-Methyl-benzylidene)-N'-[6-morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-hydrazine, having improved bioavailability, solubility, melting point and stability, used for the treatment of interleukin-12 (IL-12) related diseases or disorders
12/22/2005US20050282801 Novel phenantridine analogues and uses thereof
12/22/2005US20050282800 Method of synthesis and isolation of solid N-desmethylclozapine and crystalline forms thereof
12/22/2005US20050282799 Method of treating lower urinary tract disorders
12/22/2005US20050282798 Pharmaceutical compounds
12/22/2005US20050282797 Reacting oximinostilbene with chlorosulfonyl isocyanate in an inert organic solvent and isolating and hydrolyzing reaction product; use in treatment of epilepsy
12/22/2005US20050282796 Tetracyclic azepinoindole compounds
12/22/2005US20050282795 Antitumor agent; Quinolyl Germanyl Propionate Sesquioxide
12/22/2005US20050282794 Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
12/22/2005US20050282793 Steroid prodrugs with androgenic action
12/22/2005US20050282792 Calcitriol/clobetasol propionate compositions for the treatment of psoriasis
12/22/2005US20050282791 18-nor steroids as selectively active estrogens
12/22/2005US20050282790 Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
12/22/2005US20050282789 administering for treatment of metabolic bone diseases, mobilizing calcium for osteoporosis, imbalances in the immune system
12/22/2005US20050282788 Pharmaceutical compositions comprising silicones and two solubilized active principles
12/22/2005US20050282787 Synthesis of tetracyclines and analogues thereof
12/22/2005US20050282786 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations
12/22/2005US20050282785 For reduction of mucositis induced by radiation therapy; anticancer agents; side effect reduction; self-preserving
12/22/2005US20050282784 Therapy using a combination of raloxifene and alendronate
12/22/2005US20050282783 Obtained by reacting sodium zoledronate with calcium orthophosphates in water, bone remodeling equilibrium; the local treatment of a bone problem on the main at-risk sites identified (neck of the femur )
12/22/2005US20050282782 Lewis acid mediated synthesis of cyclic esters
12/22/2005US20050282781 Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
12/22/2005US20050282780 benzoxazoles derivatives such as 2-(4-Trifluoromethoxy-phenyl)-benzooxazole-5-carboxylic acid, used for the treatment of Alzheimer's disease, spongiform encephalopathy, polyneuropathy, cardiomyopathy, non-insulin dependent diabetes and medullary carcinoma of the thyroid
12/22/2005US20050282779 Boron complexation strategy for use in manipulating 1-acyldipyrromethanes
12/22/2005US20050282778 Combining 1-monoacyldipyrromethane with a boron compound to produce a metal complex
12/22/2005US20050282776 Injectable pharmaceutical compositions comprising sodium diclofenac and beta-cyclodextrin
12/22/2005US20050282775 Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
12/22/2005US20050282774 Method and pharmaceutical to treat spinal discs
12/22/2005US20050282773 Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer
12/22/2005US20050282772 New dietary supplement composition for obesity and inflammation
12/22/2005US20050282771 treating bleeding disorder selected from a chronic or acute bleeding disorder, a congenital coagulation disorder caused by a blood factor deficiency, and an acquired coagulation disorder, by administering a composition comprising a procoagulant amount of a fucoidan
12/22/2005US20050282770 Synthetic glycosulfopeptides and methods of synthesis thereof
12/22/2005US20050282769 Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
12/22/2005US20050282768 Cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes
12/22/2005US20050282767 Inhibitors of epoxide hydrolases for the treatment of hypertension
12/22/2005US20050282766 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
12/22/2005US20050282762 Antisense oligonucleotides for treating atopic diseases and neoplastic cell proliferation
12/22/2005US20050282761 Modulation of growth hormone receptor expression and insulin-like growth factor expression
12/22/2005US20050282759 Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
12/22/2005US20050282758 6-11 Bicyclic ketolide derivatives
12/22/2005US20050282757 Peptide boronic acid compounds useful in anticoagulation
12/22/2005US20050282752 IL-1ra variants
12/22/2005US20050282751 Therapeutic agent for renal anemia
12/22/2005US20050282750 reducing, prevention, reverse cholesterol transportation; supplying apolipoprotein
12/22/2005US20050282742 Such as bortezomib, by freeze drying
12/22/2005US20050282733 Differentiation modulating agents and uses therefor
12/22/2005US20050282732 immunology moderator; -bromoo-3-hydroxyandrostan-17-one with excipients; prevent viral reproduction
12/22/2005US20050282730 xanthocillin analogues such as 3,3'-Dimethoxyxanthocillin X dimethyl ether, used for increasing platelets in a human having a disease selected from thrombocytopenia caused by bone marrow grafting, surgery, infection, intestinal bleeding, anemia, myelodysplastic syndrome, and thrombopoietin deficiency
12/22/2005US20050282236 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
12/22/2005US20050282216 Purified polypeptides having IL-13 receptor activity
12/22/2005US20050282210 Vaccination of skunks and/or mongooses against rabies
12/22/2005US20050282165 Diagnosis of Carcinoma Using RAIG1 Polypeptides
12/22/2005US20050282157 Using oligonucleotide and peptide nucleic acid oligomers for use as diagnostic tool in monitoring cytosine methylation; detecting cell proliferative, inflammatory, connective, bone, nervous system and cardiovascular disorders
12/22/2005US20050282143 Use of visible light at wavelengths of 500 nm and higher to pathogen reduce blood and blood components
12/22/2005US20050281926 Topical application of marine oils to food
1 ... 4425 4426 4427 4428 4429 4430 4431 4432 4433 4434 4435 4436 4437 4438 4439 4440 4441 4442 4443 4444 4445 ... 7860